EATG » CHMP recommends extension of therapeutic indications for Isentress

CHMP recommends extension of therapeutic indications for Isentress

At its February meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended an extension of therapeutic indications for Isentress (raltegravir) with marketing authorisation holder Merck Sharp & Dohme Limited.

Summary of opinion for Isentress is available here.

Source:
EMA
News categories: HIV treatment, EMA/FDA